PL4240396T3 - mRNA IFN-lambda do leczenia zakażeń wirusowych - Google Patents
mRNA IFN-lambda do leczenia zakażeń wirusowychInfo
- Publication number
- PL4240396T3 PL4240396T3 PL21805509.3T PL21805509T PL4240396T3 PL 4240396 T3 PL4240396 T3 PL 4240396T3 PL 21805509 T PL21805509 T PL 21805509T PL 4240396 T3 PL4240396 T3 PL 4240396T3
- Authority
- PL
- Poland
- Prior art keywords
- ifn
- viral infections
- treating viral
- lambda mrna
- lambda
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20205674 | 2020-11-04 | ||
| PCT/EP2021/080658 WO2022096582A1 (en) | 2020-11-04 | 2021-11-04 | Use of ifn-lambda mrna for treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4240396T3 true PL4240396T3 (pl) | 2025-04-22 |
Family
ID=73059724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21805509.3T PL4240396T3 (pl) | 2020-11-04 | 2021-11-04 | mRNA IFN-lambda do leczenia zakażeń wirusowych |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20240181011A1 (pl) |
| EP (2) | EP4240396B1 (pl) |
| JP (1) | JP7851624B2 (pl) |
| KR (1) | KR20230104140A (pl) |
| CN (2) | CN120285155A (pl) |
| AU (1) | AU2021375281A1 (pl) |
| CA (1) | CA3196195A1 (pl) |
| DK (1) | DK4240396T5 (pl) |
| ES (1) | ES3018013T3 (pl) |
| FI (1) | FI4240396T3 (pl) |
| IL (1) | IL302689B2 (pl) |
| MX (1) | MX2023005302A (pl) |
| PL (1) | PL4240396T3 (pl) |
| PT (1) | PT4240396T (pl) |
| WO (1) | WO2022096582A1 (pl) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2299429C (en) | 1997-08-13 | 2010-04-20 | Biontex Laboratories Gmbh | New lipopolyamines,their preparation and the use thereof |
| GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| JP5172679B2 (ja) * | 2005-09-09 | 2013-03-27 | インペリアル イノベーションズ リミテッド | 呼吸器疾患の治療のためのインターフェロン−λ療法 |
| FR2925491B1 (fr) | 2007-12-19 | 2010-09-03 | Oz Biosciences Sas | Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules |
| EP3165234B1 (de) | 2009-07-31 | 2019-04-03 | ethris GmbH | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
| US12064484B2 (en) | 2013-06-28 | 2024-08-20 | Ethris Gmbh | Compositions for introducing RNA into cells |
| EP3542825A1 (en) * | 2014-11-10 | 2019-09-25 | Ethris GmbH | Induction of osteogenesis by delivering bmp encoding rna |
| EP3173092B1 (en) * | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| ES2835051T3 (es) | 2016-03-31 | 2021-06-21 | Ethris Gmbh | Secuencias de UTR mínimas novedosas |
| TW202428301A (zh) * | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
-
2021
- 2021-11-04 WO PCT/EP2021/080658 patent/WO2022096582A1/en not_active Ceased
- 2021-11-04 CA CA3196195A patent/CA3196195A1/en active Pending
- 2021-11-04 EP EP21805509.3A patent/EP4240396B1/en active Active
- 2021-11-04 PL PL21805509.3T patent/PL4240396T3/pl unknown
- 2021-11-04 JP JP2023526600A patent/JP7851624B2/ja active Active
- 2021-11-04 AU AU2021375281A patent/AU2021375281A1/en active Pending
- 2021-11-04 KR KR1020237014249A patent/KR20230104140A/ko not_active Ceased
- 2021-11-04 US US18/035,249 patent/US20240181011A1/en active Pending
- 2021-11-04 FI FIEP21805509.3T patent/FI4240396T3/fi active
- 2021-11-04 ES ES21805509T patent/ES3018013T3/es active Active
- 2021-11-04 DK DK21805509.3T patent/DK4240396T5/da active
- 2021-11-04 PT PT218055093T patent/PT4240396T/pt unknown
- 2021-11-04 IL IL302689A patent/IL302689B2/en unknown
- 2021-11-04 MX MX2023005302A patent/MX2023005302A/es unknown
- 2021-11-04 EP EP24221858.4A patent/EP4553084A3/en active Pending
- 2021-11-04 CN CN202510472800.1A patent/CN120285155A/zh active Pending
- 2021-11-04 CN CN202180074507.XA patent/CN117729930A/zh active Pending
-
2025
- 2025-06-24 US US19/248,327 patent/US20250319160A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK4240396T3 (da) | 2025-03-17 |
| MX2023005302A (es) | 2023-05-25 |
| EP4240396B1 (en) | 2025-01-01 |
| US20240181011A1 (en) | 2024-06-06 |
| PT4240396T (pt) | 2025-03-26 |
| JP2023548498A (ja) | 2023-11-17 |
| KR20230104140A (ko) | 2023-07-07 |
| CA3196195A1 (en) | 2022-05-12 |
| EP4553084A2 (en) | 2025-05-14 |
| ES3018013T3 (en) | 2025-05-14 |
| IL302689B1 (en) | 2025-12-01 |
| IL302689B2 (en) | 2026-04-01 |
| CN120285155A (zh) | 2025-07-11 |
| AU2021375281A1 (en) | 2023-06-01 |
| US20250319160A1 (en) | 2025-10-16 |
| EP4240396A1 (en) | 2023-09-13 |
| DK4240396T5 (da) | 2025-04-07 |
| WO2022096582A1 (en) | 2022-05-12 |
| IL302689A (en) | 2023-07-01 |
| FI4240396T3 (fi) | 2025-03-31 |
| JP7851624B2 (ja) | 2026-04-27 |
| EP4553084A3 (en) | 2025-11-26 |
| CN117729930A (zh) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3651734T3 (pl) | Kompozycje zawierające inhibitor polimerazy rna i cyklodekstrynę do leczenia infekcji wirusowych | |
| PL4157272T3 (pl) | Remdesiwir do leczenia zakażeń wirusowych | |
| IL280327A (en) | Thiazolide compounds for the treatment of viral infections | |
| ZA202202370B (en) | Compositions and methods for treating viral infections | |
| IL285232A (en) | Preparations containing oleandrin for the treatment of viral infection | |
| EP3675813A4 (en) | METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS | |
| EP4243809A4 (en) | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | |
| ZA202212662B (en) | Use of compounds for treating viral infections | |
| PL3658174T3 (pl) | Laktoferycyna i laktoferampina do leczenia infekcji | |
| HUE067223T2 (hu) | Hibrid interferonok vírusfertõzések kezelésére | |
| GB201907493D0 (en) | Agents and methods for treating viral infections | |
| GB201918341D0 (en) | Cells for treating infections | |
| IL288713A (en) | Methods for treating viral infections | |
| PT4240396T (pt) | Utilização de arnm de ifn-lambda, para o tratamento de infeções virais | |
| HUE067327T2 (hu) | Vírusos légúti fertõzések kezelése | |
| HK40089079A (en) | Pde3 inhibitors for treating viral infections | |
| GB202105509D0 (en) | Viral infections | |
| IL309452A (en) | Preparations for the treatment of viral infections and methods thereof | |
| GB202020320D0 (en) | Viral infections | |
| GB202018571D0 (en) | Viral infections | |
| GB202018446D0 (en) | Viral infections | |
| GB202013976D0 (en) | Viral infections | |
| GB202010271D0 (en) | Viral infections | |
| HK40076807A (en) | Compositions and methods for treating viral infections | |
| EP4167989A4 (en) | COMPOSITION FOR THE TREATMENT OF VIRUS INFECTIONS |